101 related articles for article (PubMed ID: 25054447)
1. The role of HE4 in ovarian cancer follow-up: a review.
Piovano E; Attamante L; Macchi C; Cavallero C; Romagnolo C; Maggino T; Landoni F; Gadducci A; Sartori E; Gion M; Zola P
Int J Gynecol Cancer; 2014 Oct; 24(8):1359-65. PubMed ID: 25054447
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature.
Capriglione S; Luvero D; Plotti F; Terranova C; Montera R; Scaletta G; Schirò T; Rossini G; Benedetti Panici P; Angioli R
Med Oncol; 2017 Aug; 34(9):164. PubMed ID: 28825178
[TBL] [Abstract][Full Text] [Related]
3. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review.
Scaletta G; Plotti F; Luvero D; Capriglione S; Montera R; Miranda A; Lopez S; Terranova C; De Cicco Nardone C; Angioli R
Expert Rev Anticancer Ther; 2017 Sep; 17(9):827-839. PubMed ID: 28756722
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of serum and tissue HE4 expression in ovarian cancer: a systematic review with meta-analysis of 90 studies.
Cao H; You D; Lan Z; Ye H; Hou M; Xi M
Expert Rev Mol Diagn; 2018 Apr; 18(4):371-383. PubMed ID: 29569984
[TBL] [Abstract][Full Text] [Related]
5. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
6. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
7. MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors.
Cymbaluk-Ploska A; Chudecka-Glaz A; Surowiec A; Pius-Sadowska E; Machalinski B; Menkiszak J
Asian Pac J Cancer Prev; 2016; 17(5):2597-603. PubMed ID: 27268637
[TBL] [Abstract][Full Text] [Related]
8. Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?
Chudecka-Głaz A; Cymbaluk-Płoska A; Wężowska M; Menkiszak J
PLoS One; 2018; 13(3):e0194270. PubMed ID: 29584739
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
[TBL] [Abstract][Full Text] [Related]
10. Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy.
Teh BH; Yong SL; Sim WW; Lau KB; Suharjono HN
Horm Mol Biol Clin Investig; 2018 Jul; 35(1):. PubMed ID: 30063463
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of serum HE4 levels and risk of ovarian malignancy algorithm scores at the time of ovarian cancer diagnosis.
Kaijser J; Van Belle V; Van Gorp T; Sayasneh A; Vergote I; Bourne T; Van Calster B; Timmerman D
Int J Gynecol Cancer; 2014 Sep; 24(7):1173-80. PubMed ID: 24987915
[TBL] [Abstract][Full Text] [Related]
12. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse.
Braicu EI; Chekerov R; Richter R; Pop C; Nassir M; Loefgren H; Stamatian F; Muallem MZ; Hall C; Fotopoulou C; Sehouli J; Pietzner K
Ann Surg Oncol; 2014 Mar; 21(3):955-62. PubMed ID: 24217786
[TBL] [Abstract][Full Text] [Related]
13. The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program.
Angioli R; Capriglione S; Scaletta G; Aloisi A; Miranda A; De Cicco Nardone C; Terranova C; Plotti F
Tumour Biol; 2016 Apr; 37(4):4973-8. PubMed ID: 26531723
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of HE4 for ovarian cancer: a meta-analysis.
Yu S; Yang HJ; Xie SQ; Bao YX
Clin Chem Lab Med; 2012 Feb; 50(8):1439-46. PubMed ID: 22868811
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125.
Zheng X; Chen S; Li L; Liu X; Liu X; Dai S; Zhang P; Lu H; Lin Z; Yu Y; Li G
J Gynecol Obstet Hum Reprod; 2018 Jun; 47(6):227-230. PubMed ID: 29609043
[TBL] [Abstract][Full Text] [Related]
16. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
17. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.
Goff BA; Agnew K; Neradilek MB; Gray HJ; Liao JB; Urban RR
Gynecol Oncol; 2017 Nov; 147(2):291-295. PubMed ID: 28860006
[TBL] [Abstract][Full Text] [Related]
18. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients.
Abbink K; Zusterzeel PL; Geurts-Moespot AJ; Herwaarden AEV; Pijnenborg JM; Sweep FC; Massuger LF
Tumour Biol; 2018 Feb; 40(2):1010428318757103. PubMed ID: 29463191
[TBL] [Abstract][Full Text] [Related]
19. [HE4 a biomarker of ovarian cancer].
Presl J; Kučera R; Topolčan O; Novotný Z; Vrzalová J; Fuchsova R; Betincová L; Rokyta Z
Ceska Gynekol; 2012 Oct; 77(5):445-9. PubMed ID: 23116350
[TBL] [Abstract][Full Text] [Related]
20. Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers.
Li J; Chen H; Curcuru JR; Patel S; Johns TO; Patel D; Qian H; Jiang SW
Curr Drug Targets; 2017; 18(10):1158-1164. PubMed ID: 28382859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]